In order to further investigate whether the activity of the predicted RELAPSE-activated kinases was essential for cell survival and proliferation, we tested the proliferation in available AML cells from ten RELAPSE and nine REL_FREE patients in the presence of inhibitors of CSK2, CDK2/7/9, CDK4/6 and ERK1/2, alone or in combination (Table S5). The gene discussed is MAPK3; the disease is acute myeloid leukemia.